Revolution Medicines, Inc. (RVMDW)

Market Cap	7.16B
Revenue (ttm)	n/a
Net Income (ttm)	-812.06M
Shares Out	186.93M
EPS (ttm)	-4.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,662
Open	0.1750
Previous Close	0.1872
Day's Range	0.1651 - 0.1750
52-Week Range	0.0305 - 0.8000
Beta	1.16
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About RVMDW

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 534
• Stock Exchange: NASDAQ
• Ticker Symbol: RVMDW
• Website: https://www.revmed.com